IQVIA Holdings Inc. (NYSE:IQV) Short Interest Update

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) saw a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 7,200,000 shares, a growth of 29.3% from the May 15th total of 5,570,000 shares. Approximately 4.2% of the shares of the company are sold short. Based on an average trading volume of 2,290,000 shares, the short-interest ratio is currently 3.1 days.

Institutional Trading of IQVIA

Several large investors have recently modified their holdings of the business. Empowered Funds LLC raised its position in shares of IQVIA by 40.0% in the 4th quarter. Empowered Funds LLC now owns 4,813 shares of the medical research company's stock valued at $946,000 after purchasing an additional 1,376 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in IQVIA in the fourth quarter valued at $60,000. Bruni J V & Co. Co. bought a new position in IQVIA during the 4th quarter valued at $13,304,000. Metis Global Partners LLC grew its holdings in IQVIA by 19.5% during the 4th quarter. Metis Global Partners LLC now owns 10,023 shares of the medical research company's stock worth $1,970,000 after acquiring an additional 1,633 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in IQVIA by 57.0% during the 4th quarter. Jones Financial Companies Lllp now owns 1,215 shares of the medical research company's stock worth $239,000 after acquiring an additional 441 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Redburn Partners set a $188.00 target price on shares of IQVIA in a research report on Friday, May 23rd. Truist Financial decreased their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Hsbc Global Res downgraded IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. dropped their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $226.32.

IQVIA Trading Down 3.2%

Shares of IQVIA stock traded down $5.15 during trading hours on Tuesday, reaching $154.10. The stock had a trading volume of 2,631,045 shares, compared to its average volume of 1,625,744. The firm has a market capitalization of $26.66 billion, a price-to-earnings ratio of 20.99, a P/E/G ratio of 1.74 and a beta of 1.28. IQVIA has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The firm has a 50 day simple moving average of $147.89 and a two-hundred day simple moving average of $177.05.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. IQVIA's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.54 earnings per share. As a group, equities research analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.